Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide
Begoña López (1), Arantxa González (1), Nerea Hermida (1), Concepción Laviades (2) and Javier Díez (1,3)
(1) Division of Cardiovascular Sciences, Center of Applied Medical Research, University of Navarra, Pamplona, Spain
(2) Section of Nephrology, San Jorge General Hospital, Huesca, Spain
(3) Department of Cardiology and Cardiovascular Surgery, University Clinic, University of Navarra, Pamplona, Spain
Interstitial and perivascular fibrosis is a constant finding in heart biopsies and necropsy studies in patients with chronic kidney disease and hypertension, namely in those with left ventricular hypertrophy. Fibrosis is the result of the unbalance between exaggerated collagen synthesis and unchanged or depressed collagen degradation. A number of factors linked to hypertension and the progressive deterioration of renal function may facilitate such an unbalance.
Patients with chronic kidney disease and hypertension are prone to develop diastolic heart failure, and myocardial fibrosis has been suggested as a major determinant of disturbances in diastolic function in these patients. Thus, the therapeutic strategies aimed to reduce cardiac fibrosis may provide a particular cardioprotective benefit in patients with chronic kidney disease.
In this regard, recent data suggest that the loop diuretic torasemide reduces myocardial fibrosis and ameliorates cardiac function in patients with chronic heart failure through local mechanisms beyond its effects on the renal excretion of fluid and electrolytes and systemic hemodynamics.
CITATION Kidney Int Suppl. 2008 Dec;(111):S19-23